Aprea Therapeutics Inc is a biotechnology business based in the US. Aprea Therapeutics shares (APRE) are listed on the NASDAQ and all prices are listed in US Dollars.
How to buy shares in Aprea Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – APRE – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Aprea Therapeutics stock price (NASDAQ: APRE)
Use our graph to track the performance of APRE stocks over time.Aprea Therapeutics shares at a glance
Latest market close | $0.78 |
---|---|
52-week range | $0.62 - $5.89 |
50-day moving average | $1.02 |
200-day moving average | $2.71 |
Wall St. target price | $2.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.65 |
Buy Aprea Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Aprea Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Aprea Therapeutics price performance over time
Historical closes compared with the close of $0.775 from 2022-07-01
1 week (2022-06-27) | -9.46% |
---|---|
1 month (2022-06-01) | 1.31% |
3 months (2022-04-01) | -58.11% |
6 months (2022-01-04) | -74.76% |
1 year (2021-07-02) | -85.27% |
---|---|
2 years (2020-07-02) | -97.88% |
3 years (2019-06-30) | N/A |
5 years (2017-06-30) | N/A |
Aprea Therapeutics financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -33.78% |
Return on equity TTM | -62.79% |
Profit margin | 0% |
Book value | $1.98 |
Market capitalisation | $17.5 million |
TTM: trailing 12 months
Aprea Therapeutics share dividends
We're not expecting Aprea Therapeutics to pay a dividend over the next 12 months.
Aprea Therapeutics share price volatility
Over the last 12 months, Aprea Therapeutics's shares have ranged in value from as little as $0.62 up to $5.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aprea Therapeutics's is 0.1664. This would suggest that Aprea Therapeutics's shares are less volatile than average (for this exchange).
Aprea Therapeutics overview
Aprea Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts. .
Frequently asked questions
What percentage of Aprea Therapeutics is owned by insiders or institutions?Currently 9.842% of Aprea Therapeutics shares are held by insiders and 20.652% by institutions. When does the fiscal year end for Aprea Therapeutics?
Aprea Therapeutics's fiscal year ends in December. Where is Aprea Therapeutics based?
Aprea Therapeutics's address is: 535 Boylston St., Boston, MA, United States, 02116 What is Aprea Therapeutics's ISIN number?
Aprea Therapeutics's international securities identification number is: US03836J1025 What is Aprea Therapeutics's CUSIP number?
Aprea Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03836J102
More guides on Finder
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
-
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
-
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
-
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert